1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Alkermes ENLIGHTEN Hints At Efficacy Benefit But Weight Profile Still In Balance

 
• By Alexandra Shimmings

The first Phase III trial results for Alkermes' combination product for schizophrenia ALKS 3831 show hints of added benefit over olanzapine alone but no benefit yet on weight gain, the product's raison d'être. Analysts are hoping upcoming longer-term data will produce the goods.

Zen stones
ENLIGHTEN Benefits Weighed In The Balance • Source: Shutterstock

The first of two Phase III ENLIGHTEN studies for Alkermes PLC's combination product for schizophrenia, ALKS 3831, show it has at least equivalent efficacy to olanzapine alone, but the study was too short to tell whether the combination can lessen the weight gain problem that plagues the older product.

The broad-spectrum antipsychotic product contains the novel drug samidorphan co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

More from R&D

In Brief: Gilead HIV Trials On Hold Over Safety Signal

 
• By Sushmita Panda

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

Pharma’s Space Trails Entering Transformative Era - Keytruda’s Been There

 
• By Anju Ghangurde

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.